Project Grant R01CA301448
Award Date 9/1/25
Completion Date 8/31/29
Dollars Obligated $498K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Emory University provides $158,899 to establish an innovative platform for simultaneous intensity, energy modulation, and compensation (SIEMAC) optimization. This will enable conformal flash proton therapy for the treatment of central lung cancer, which aims to reduce toxicity to organs at risk while maintaining tumor control. The grant also supports the development of a quality assurance...
- This Project Grant award from the National Cancer Institute's (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund a research project titled "Innovative Scan Protocols with Combined Long Axial FOV PET and Spectral CT for Improved Quantification in Oncology". The $666,670 award, effective January 15, 2025, aims to develop advanced imaging protocols and processing techniques that utilize both positron emission tomography (PET) and spectral computed tomography (CT) to enhance...
- This federal Project Grant award of $695,814 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) supports research to develop artificial intelligence (AI) technologies that enable online adaptive radiation therapy for proton therapy. The key products and services to be delivered through this grant include: 1) Developing an asymmetric autoencoder network...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $736,168 to the Sloan-Kettering Institute for Cancer Research to develop first-in-class antibody-drug conjugates (ADCs) and payloads specifically designed for combination with external beam radiotherapy. The key products and services to be delivered include: Developing HER2-directed ADCs containing DNA damage response inhibitors as payloads, which have demonstrated efficacy in vitro and...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Rochester provides $639,098 to develop an innovative treatment for metastatic pancreatic cancer. The research aims to overcome both intrinsic and extrinsic barriers to treatment efficacy, specifically by targeting the tumor microenvironment through a combination of local radiotherapy and intratumoral immunotherapy using a novel mRNA-based nanoparticle delivery system. The...
- This federal Project Grant award of $545,078, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is supporting research at The Johns Hopkins University to investigate the use of radiopharmaceutical therapy in combination with inhibition of glutamine metabolism as a novel therapeutic strategy for prostate cancer and renal cell carcinoma. The project aims to systematically evaluate the effect of prostate-specific membrane antigen (PSMA)-based radiopharmaceutical...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $585,976 to Providence Health & Services - Oregon to conduct research on enhancing the efficacy of radiation therapy through spatially restricted anti-TGFβ treatment in the tumor microenvironment. The key objectives are to determine the role of self-renewing stem-like CD8+ T cells in local and distant radiation response, and to test radiation therapy combined with...
- The Department of Health and Human Services' National Cancer Institute awarded a $644,034 Project Grant on March 11, 2025 under the Cancer Treatment Research (CFDA 93.395) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant is for the development of a "scintillating nanoparticle drug depot (SCIDD) platform" that uses nanoparticles to convert X-ray energy into light, which can then release potent and tumor-penetrating...
- This $391,826 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Trustees of the University of Pennsylvania aims to develop a novel polyphosphazene nanoparticle (PPNP) platform to enhance photothermal therapy and deliver a heat shock protein (HSP) inhibitor for the treatment of breast cancer. The key products and services to be delivered under this award include: Synthesizing, characterizing, and testing the PPNP nanoparticles...
- This $375,134 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can be leveraged to limit nanoparticle deposition in healthy tissues, thereby enhancing delivery to tumors and improving the efficacy of chemotherapy. The 5-year project, starting on March 1, 2025,...